https://orcid.org/0000-0002-9868-6308
Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Bettina Wedi. (2023) Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development. Expert Opinion on Investigational Drugs 32:11, pages 1043-1054.
Read now
Read now
Bettina Wedi. (2022) Emerging treatments for chronic urticaria. Expert Opinion on Investigational Drugs 31:3, pages 281-290.
Read now
Read now
Articles from other publishers (12)
Deepa Chaturvedi, Swarali Paranjape, Ratnesh Jain & Prajakta Dandekar. (2023) Disease-related biomarkers as experimental endpoints in 3D skin culture models. Cytotechnology 75:3, pages 165-193.
Crossref
Crossref
Henry C. Ezechukwu, Oyelola A. Adegboye, Wahab O. Okunowo & Theophilus I. Emeto. (2023) Targeting IgE and Th2-Cytokines in Allergy: Brief Updates on Monoclonal Antibodies and Antibody Gene Therapy. Allergies 3:2, pages 90-104.
Crossref
Crossref
Cristina Benito‐Villalvilla, Andrés de la Rocha‐Muñoz, Jacobo López‐Abente, Alexander Eggel, Iván Bottoli, Thomas Severin, Maximilian Woisetschläger & Oscar Palomares. (2022)
Ligelizumab impairs
IgE
‐binding to plasmacytoid dendritic cells more potently than omalizumab and restores
IFN
‐α production and
FOXP3
+
Treg generation
. Allergy 78:4, pages 1060-1072.
Crossref
Crossref
Ramón Gimeno, Clara Ribas‐Llauradó, David Pesque, Evelyn Andrades, Bruno Cenni, Barbara Ambros, Ramon Pujol & Ana M. Giménez‐Arnau. (2023) Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response. Clinical and Translational Allergy 13:3.
Crossref
Crossref
Yang Li, Patrick S. C. Leung, M. Eric Gershwin & Junmin Song. (2022) New Mechanistic Advances in FcεRI-Mast Cell–Mediated Allergic Signaling. Clinical Reviews in Allergy & Immunology 63:3, pages 431-446.
Crossref
Crossref
Evangelia Diamanti, Julia Föhr, Andria Papageorgiou, Matthias Herbst & Sigbert Jahn. (2022) Anti-IgE-gerichtete Therapie der Urtikaria in der dermatologischen PraxisAnti-IgE-directed treatment of urticaria in a dermatological practice. Die Dermatologie 73:10, pages 788-794.
Crossref
Crossref
Zhao Wang, Zhuoran Li, Gürkan Bal, Kristin Franke, Torsten Zuberbier & Magda Babina. (2022) β-arrestin-1 and β-arrestin-2 Restrain MRGPRX2-Triggered Degranulation and ERK1/2 Activation in Human Skin Mast Cells. Frontiers in Allergy 3.
Crossref
Crossref
Olguța Anca Orzan, Liliana Gabriela Popa, Mara Mădălina Mihai, Anca Cojocaru, Călin Giurcăneanu & Alexandra Maria Dorobanțu. (2022) Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies. Medicina 58:6, pages 816.
Crossref
Crossref
Beibei Zhu, Yi Liu, Jing Li, Qi Ni, Zheng Yin, Junli Zhu, Ken Chen & Xueyuan Yang. (2022) Biologics for Non-Cancer Dermatological Diseases: Analysis on China’s Clinical Trial Registration Trend From 2016 to 2020. Frontiers in Pharmacology 13.
Crossref
Crossref
Barbora Jankovičová. (2022) Current view on urticaria - causes of urticaria occurrence, diagnosis and current treatment options. Dermatologie pro praxi 16:1, pages 13-16.
Crossref
Crossref
Ana M. Giménez‐Arnau, Clara Ribas‐Llauradó, Nasser Mohammad‐Porras, Gustavo Deza, Ramón M. Pujol & Ramón Gimeno. (2022) IgE and high‐affinity IgE receptor in chronic inducible urticaria, pathogenic, and management relevance. Clinical and Translational Allergy 12:2.
Crossref
Crossref
Bettina Wedi. (2021) Contemporary Grand Challenges and Opportunities in Skin Allergies. Frontiers in Allergy 2.
Crossref
Crossref